BioXcel Therapeutics Inc
Research BioXcel Therapeutics Inc (BTAI) on Bullrun: market cap USD 23.23M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBTAI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 23.23M
- Financial periodQ1 2026
- RevenueUSD 206.00K
- Net income-USD 75.33M
- Free cash flow-USD 11.81M
- Gross margin119.9%
Valuation Snapshot
latest market cap is USD 23.23M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 642.00K | -USD 69.90M | -USD 57.62M | 74.5% | -5.73 | USD 28.42M | USD 109.59M | -USD 95.46M |
| FY2024 | USD 2.27M | -USD 59.60M | -USD 72.03M | 5.4% | -23.51 | USD 29.85M | USD 102.51M | -USD 93.10M |
| FY2023 | USD 1.38M | -USD 179.05M | -USD 155.03M | 8.7% | -98.33 | USD 65.22M | USD 100.60M | -USD 56.51M |
| FY2022 | USD 375.00K | -USD 165.76M | -USD 135.48M | 94.7% | -5.92 | USD 193.73M | USD 93.05M | USD 76.78M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 23.23M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 35.72M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 18.55M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 86.35M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 601.96M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 568.85M | n/a | n/a | n/a |
About BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioXcel Therapeutics Inc's market cap?
BioXcel Therapeutics Inc's market capitalization is USD 23.23M.
What does BioXcel Therapeutics Inc do?
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.